Tirzepatide vs retatrutide is not an even comparison in August 2026, and the reason is availability rather than potency. Tirzepatide is a dual GIP/GLP-1 receptor agonist with completed phase 3 trials and approved U.S. indications, and a licensed prescriber can write for it today. Retatrutide is an investigational triple agonist — GIP, GLP-1 and glucagon — with published phase 2 results and a phase 3 programme still reporting. It is not approved in the United States and cannot be prescribed here outside a clinical trial.
Tirzepatide vs retatrutide at a glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GIP and GLP-1 — a dual agonist | GIP, GLP-1 and glucagon — a triple agonist |
| Development stage | Phase 3 complete; several programmes published | Phase 2 published; phase 3 TRIUMPH trials still reporting |
| U.S. regulatory status | Approved under two brand names for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea | Investigational; no approved indication |
| Who can obtain it | Anyone a licensed prescriber judges appropriate, as the brand product or a compounded preparation | Clinical-trial participants only |
| Largest published weight result | −20.9% at 72 weeks on 15 mg (SURMOUNT-1, phase 3, 2,539 adults) | −24.2% at 48 weeks on 12 mg (phase 2, 338 adults) |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
Those two weight figures come from different trials, at different durations, in different populations, so the gap between them is not a measured difference between the two molecules. The only direct comparison — a phase 3 trial comparing retatrutide with tirzepatide in adults with obesity — is under way and has not reported.
Two receptors, three receptors
Tirzepatide activates two incretin receptors: GIP and GLP-1. GIP and GLP-1 are incretin hormones involved in glucose-dependent insulin release, but a randomized human experiment did not find that native GIP slowed gastric emptying or suppressed appetite. The mechanism is covered in more depth in how tirzepatide works.
Retatrutide adds a third target, the glucagon receptor. Glucagon is usually thought of as the hormone that raises blood sugar, which sounds like the opposite of what you would want. The design logic is that glucagon receptor agonism also increases energy expenditure and mobilises fat from the liver, while the GLP-1 component offsets the glucose-raising effect. Whether that third arm delivers a durable advantage in people, and at what cost in tolerability, is precisely what the phase 3 programme exists to answer.
What tirzepatide has already shown
The phase 3 obesity trial SURMOUNT-1 randomised 2,539 adults with obesity, or overweight plus a weight-related complication, to tirzepatide or placebo for 72 weeks. Mean weight change was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo (Jastreboff et al., New England Journal of Medicine 2022). Gastrointestinal events were the most common adverse events and were mostly mild to moderate, occurring largely during dose escalation.
In type 2 diabetes, SURPASS-2 compared tirzepatide head-to-head against semaglutide over 40 weeks (Frías et al., New England Journal of Medicine 2021). That trial is one reason tirzepatide became a standard point of comparison rather than a newcomer.
On the regulatory side, tirzepatide is approved in the United States under two brand names: as Mounjaro for type 2 diabetes, and as Zepbound for chronic weight management and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.
Where retatrutide's evidence actually stands
The phase 2 obesity trial enrolled 338 adults and ran 48 weeks. Mean weight change at 48 weeks was −8.7% on 1 mg, −17.1% on 4 mg, −22.8% on 8 mg and −24.2% on 12 mg, against −2.1% on placebo (Jastreboff et al., New England Journal of Medicine 2023). Adverse events were dose-related and mainly gastrointestinal, and dose-dependent heart-rate increases peaked at 24 weeks before declining.
Phase 3 data have begun to appear. TRANSCEND-T2D-1, a 40-week trial in 537 adults with type 2 diabetes not controlled by diet and exercise, reported HbA1c reductions of 1.69% to 1.94% and weight reductions of 11.5% to 15.3% across three doses (Bajaj et al., The Lancet 2026). The obesity programme, TRIUMPH, is a four-trial registrational set in more than 5,800 participants (Giblin et al., Diabetes, Obesity and Metabolism 2026). The manufacturer released topline TRIUMPH-1 results in May 2026 describing average weight loss of 28.3% at 80 weeks on the 12 mg dose; that readout is a company statement and has not yet been through peer review. Our retatrutide overview tracks the molecule itself in more detail.
That is the honest shape of the comparison. One drug has a completed evidence base and a label; the other has promising numbers, a large programme in flight, and years of process ahead of it.
The comparison you can actually act on
Because retatrutide cannot be prescribed, the live decision for most people is between the two GLP-1 medications that can be. Semaglutide is a single GLP-1 receptor agonist with its own large trial record; tirzepatide adds the GIP arm. They differ in mechanism, in titration schedule, in side-effect pattern and in price, and tirzepatide versus semaglutide works through those differences properly.
Availability is the whole difference right now
Retatrutide is not FDA-approved, and it is not available by prescription in the United States. Its manufacturer states plainly that it is legally available only to participants in its clinical trials. No pharmacy dispenses it against a prescription, compounding pharmacies included, and Promise does not offer it.
Vials labelled as retatrutide are nonetheless sold online without a prescription, priced by the milligram, shipped from anonymous suppliers and labelled for laboratory use rather than for people. That material has no clinician attached, no verified identity or purity, and no accountability if the contents are wrong. It is not the trial drug; it is something sold under the trial drug's name.
What compounded tirzepatide means, precisely
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medications are prepared by a licensed pharmacy for an individual patient on a prescription, and they are not reviewed by the FDA for safety, effectiveness or quality. That distinction is worth stating flatly rather than blurring — see compounded tirzepatide for what the preparation is and is not.
Regulatory status is one input into a prescribing decision rather than the whole of it. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.
How a prescriber approaches the choice today
A clinician cannot offer retatrutide, so the conversation is not really "which of the two". It is whether an incretin medication is appropriate for you at all, and if so, which of the available ones fits your history, your other medications and how you tolerate titration.
Waiting is a legitimate answer, and some people choose it. The manufacturer plans to submit a U.S. Biologics License Application in the first quarter of 2027; phase 3 readouts are still arriving, and regulatory review would follow any submission. Waiting for a better molecule has a cost measured in years.
At Promise, a licensed provider reviews every request and prescribes only when the medication is appropriate for you. Not everyone qualifies, and nobody is charged for a prescription that is not written.